Trajectories of CD4(+)/CD8(+) T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study.

Taramasso L, Falletta A, Ricci E, Orofino G, Squillace N, Menzaghi B, De Socio GV, Molteni C, Pellicanò GF, Gulminetti R, Madeddu G, Sarchi E, Vichi F, Celesia BM, Bonfanti P, Di Biagio A, CISAI Study Group

Open source

DOI
10.3390/v14112315
Published
2022 Oct 22
Container
Viruses
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/v14112315,
  title = {Trajectories of CD4(+)/CD8(+) T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study.},
  author = {Taramasso L and Falletta A and Ricci E and Orofino G and Squillace N and Menzaghi B and De Socio GV and Molteni C and Pellicanò GF and Gulminetti R and Madeddu G and Sarchi E and Vichi F and Celesia BM and Bonfanti P and Di Biagio A and CISAI Study Group},
  year = {2022},
  journal = {Viruses},
  doi = {10.3390/v14112315},
  url = {https://doi.org/10.3390/v14112315}
}

RIS

TY  - JOUR
TI  - Trajectories of CD4(+)/CD8(+) T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study.
AU  - Taramasso L
AU  - Falletta A
AU  - Ricci E
AU  - Orofino G
AU  - Squillace N
AU  - Menzaghi B
AU  - De Socio GV
AU  - Molteni C
AU  - Pellicanò GF
AU  - Gulminetti R
AU  - Madeddu G
AU  - Sarchi E
AU  - Vichi F
AU  - Celesia BM
AU  - Bonfanti P
AU  - Di Biagio A
AU  - CISAI Study Group
PY  - 2022
JO  - Viruses
DO  - 10.3390/v14112315
UR  - https://doi.org/10.3390/v14112315
ER  - 

APA

L, T., A, F., E, R., G, O., N, S., B, M., GV, D. S., C, M., GF, P., R, G., G, M., E, S., F, V., BM, C., P, B., A, D. B., & Group, C. S. (2022). Trajectories of CD4(+)/CD8(+) T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study.. Viruses. https://doi.org/10.3390/v14112315

Source records